These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31538988)

  • 1. Patient Assistance Programs: Easing the Burden of Financial Toxicity During Cancer Treatment.
    McMullen L
    Clin J Oncol Nurs; 2019 Oct; 23(5):36-40. PubMed ID: 31538988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Patient Financial Assistance Programs in Reducing Costs for Cancer Patients.
    Zullig LL; Wolf S; Vlastelica L; Shankaran V; Zafar SY
    J Manag Care Spec Pharm; 2017 Apr; 23(4):407-411. PubMed ID: 28345445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addressing the Financial Burden of Cancer Treatment: From Copay to Can't Pay.
    Shankaran V; Ramsey S
    JAMA Oncol; 2015 Jun; 1(3):273-4. PubMed ID: 26181165
    [No Abstract]   [Full Text] [Related]  

  • 4. Patient assistance programs: a valuable, yet imperfect, way to ease the financial toxicity of cancer care.
    Yezefski T; Schwemm A; Lentz M; Hone K; Shankaran V
    Semin Hematol; 2018 Oct; 55(4):185-188. PubMed ID: 30502845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug company-sponsored patient assistance programs: a viable safety net?
    Choudhry NK; Lee JL; Agnew-Blais J; Corcoran C; Shrank WH
    Health Aff (Millwood); 2009; 28(3):827-34. PubMed ID: 19414893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Financial Eligibility Criteria and Medication Coverage for Independent Charity Patient Assistance Programs.
    Kang SY; Sen A; Bai G; Anderson GF
    JAMA; 2019 Aug; 322(5):422-429. PubMed ID: 31386135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The multidimensional nature of the financial and economic burden of a cancer diagnosis on patients and their families: qualitative findings from a country with a mixed public-private healthcare system.
    Timmons A; Gooberman-Hill R; Sharp L
    Support Care Cancer; 2013 Jan; 21(1):107-17. PubMed ID: 22987093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Financial Support Models: A Case for Use of Financial Navigators in the Oncology Setting.
    Sherman D; Fessele KL
    Clin J Oncol Nurs; 2019 Oct; 23(5):14-18. PubMed ID: 31538990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does public insurance provide better financial protection against rising health care costs for families of children with special health care needs?
    Yu H; Dick AW; Szilagyi PG
    Med Care; 2008 Oct; 46(10):1064-70. PubMed ID: 18815528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Making the Case: Clinical Assessment of Financial Toxicity.
    Carr E; Rosato E
    Clin J Oncol Nurs; 2019 Oct; 23(5):19-26. PubMed ID: 31538986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient Financial Assistance Programs: A Path to Affordability or a Barrier to Accessible Cancer Care?
    Zafar SY; Peppercorn JM
    J Clin Oncol; 2017 Jul; 35(19):2113-2116. PubMed ID: 28459612
    [No Abstract]   [Full Text] [Related]  

  • 12. Transparency of Industry-Sponsored Oncology Patient Financial Assistance Programs Using a Patient-Centered Approach.
    Zafar SY; Peppercorn J; Asabere A; Bastian A
    J Oncol Pract; 2017 Mar; 13(3):e240-e248. PubMed ID: 28140745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient assistance programs and patient advocacy foundations: alternatives for obtaining prescription medications when insurance fails.
    Johnson PE
    Am J Health Syst Pharm; 2006 Nov; 63(21 Suppl 7):S13-7. PubMed ID: 17057055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacy Assistance Programs for Oral Anticancer Drugs: A Narrative Review.
    Ragavan MV; Swartz S; Clark M; Chino F
    JCO Oncol Pract; 2024 Apr; 20(4):472-482. PubMed ID: 38241597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of trained oncology financial navigators on patient out-of-pocket spending.
    Yezefski T; Steelquist J; Watabayashi K; Sherman D; Shankaran V
    Am J Manag Care; 2018 Mar; 24(5 Suppl):S74-S79. PubMed ID: 29620814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inequalities in financial risk protection in Bangladesh: an assessment of universal health coverage.
    Islam MR; Rahman MS; Islam Z; Nurs CZ; Sultana P; Rahman MM
    Int J Equity Health; 2017 Apr; 16(1):59. PubMed ID: 28376808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic Burden Associated with Cancer Caregiving.
    Bradley CJ
    Semin Oncol Nurs; 2019 Aug; 35(4):333-336. PubMed ID: 31229344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmaceutical policies: effects of cap and co-payment on rational drug use.
    Austvoll-Dahlgren A; Aaserud M; Vist G; Ramsay C; Oxman AD; Sturm H; Kösters JP; Vernby A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD007017. PubMed ID: 18254125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addressing the Financial Burden of Cancer Clinical Trial Participation: Longitudinal Effects of an Equity Intervention.
    Nipp RD; Lee H; Gorton E; Lichtenstein M; Kuchukhidze S; Park E; Chabner BA; Moy B
    Oncologist; 2019 Aug; 24(8):1048-1055. PubMed ID: 30988039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of patient assistance programs and the 340B Drug Pricing Program on medication cost.
    Castellon YM; Bazargan-Hejazi S; Masatsugu M; Contreras R
    Am J Manag Care; 2014 Feb; 20(2):146-50. PubMed ID: 24738532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.